(NDAA)legislation was passed to combat national security and intellectual property threats that face the United States and contains two prohibitions: Part A and Part B.

- Part A went into effect last year (August 13, 2019), and prohibits the government from buying or obtaining certain prohibited telecommunications and video surveillance equipment and services.
- Part B will go into effect on (August 13, 2020), and prohibits the government from contracting with any entity that uses certain prohibited telecommunications and video surveillance equipment or services, regardless of whether or not that usage is in performance of work under a government contract. The Part B prohibition applies to every sector and every dollar amount. Your contracts will be impacted by Part B.

Format

GSA's live and recorded virtual webinar features panel leaders from GSA's business lines who will explain how they are implementing Section 889 FAR rule in their specific business lines. Panelists will also answer questions that have been pre-collected from industry. Please send in your questions no later than COB August 5, 2020, Eastern to *gsaombudsman@gsa.gov.*

Special Accommodations

This virtual meeting is accessible to people with Disabilities as Zoom has a close captioned feature.

Live Webinar Panelists

- Michael Thompson, *Senior Policy Advisor General Services Acquisition Policy Division, OGP, Moderator*
- Stephanie Shutt, *Director, Multiple Awards Schedule Program Management Office, FAS*
- Mary Gartland, *Director City Pair Program, Office of Travel, Employee Relocation, and Transportation, FAS*
- Lawrence Hale, *Director, IT Security Subcategory Office of Information Technology Category, FAS*
- Julie Milner, *Director, Special Programs Division, Office of Project Delivery, Office of Design and Construction, PBS*
- Chip Pierpont, *Director, Innovation Technology and Performance Division, Office of Facilities Management, PBS*
- Justin Hawes, *Division Director, Lease Policy and Innovation Division, Office of Leasing, PBS*
- Len Fedoruk, *Director, Vehicle Purchasing Division Office of Motor Vehicle Management, FAS*

Agenda

- 1:00–1:05: GSA Ombudsman Welcome
- 1:05–1:10: Introduction of Panel participants by GSA Moderator.
- 1:10–2:25: Panel discussion of GSA's 889 Implementation by Business lines
- 2:25–2:30: GSA Ombudsman Close out

Maria Swaby,

GSA Procurement Ombudsman & Industry Liaison, General Services Administration.

[FR Doc. 2020–15846 Filed 7–21–20; 8:45 am]

BILLING CODE 6820–61–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Management of Acute and Chronic Pain: Opportunity for Stakeholder Engagement

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces an opportunity to hear stakeholders' perspectives on and experiences with pain and pain management, including but not limited to the benefits and harms of opioid use. These stakeholders include patients with acute or chronic pain, patients' family members and/or caregivers, and healthcare providers who care for patients with pain or conditions that can complicate pain management (*e.g.,* opioid use disorder or overdose). As part of this effort, CDC will be holding approximately 100 individual conversations with stakeholders over the phone or through an internet-enabled virtual platform. CDC is asking stakeholders interested in participating to contact CDC as outlined in the **SUPPLEMENTARY INFORMATION** section. These conversations are intended to supplement the efforts of CDC's prior FRN (85 FR 21441) which solicited written public comment on the same topical areas between April and June 2020.

DATES: Persons interested in participating should contact CDC as described below no later than 5:00 p.m. EDT August 21, 2020.

FOR FURTHER INFORMATION CONTACT: Shannon Lee, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop S106–9, Atlanta, Georgia, 30329, Telephone: 404–498–3290, email: *InjuryCenterEngage@cdc.gov*

SUPPLEMENTARY INFORMATION:

Purpose

Input gathered through these conversations will help inform CDC's understanding of stakeholders' values and preferences related to pain and pain management and will complement CDC's ongoing work to update or expand the CDC Guideline for Prescribing Opioids for Chronic Pain, published in 2016 (Available at *https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1er.htm*). More information about CDC's process for updating the Guideline and the establishment of a Federal advisory committee workgroup to provide expert input and observations on the Guideline update is available at *https://www.cdc.gov/injury/bsc/opioid-workgroup-2019.html.* CDC will request public comment on the updated draft Guideline through a notice in the **Federal Register** prior to final publication.

Engagement Structure

During these conversations, CDC will talk with individual participants between 45–60 minutes on the phone or an internet-enabled virtual platform to listen to personal perspectives and experience related to the themes described below in the THEMES section.

Participation

Persons interested in participating in these conversations should email the following information to *InjuryCenterEngage@cdc.gov:*

- Full name
- Whether you would be participating primarily as a healthcare provider, patient, or family member and/or caregiver
  - If you are a healthcare provider, please describe whether you care for patients with chronic pain, acute pain, and/or conditions that can complicate pain management (*e.g.,* opioid use disorder or overdose)
  - If you are a patient, please identify if you mostly experience acute or chronic pain and if you feel opioid pain medications have mostly helped you, mostly harmed you, neither, or an even mix of both
  - If you are a family member and/or caregiver, please identify if the person you care for experiences acute or chronic pain and if you feel opioid pain medications have mostly helped or mostly harmed them, neither, or an even mix of both

Persons having trouble submitting by email or unable to submit by email should call 404–498–3290.

See PARTICIPANT SELECTION PROCEDURE below for information on how CDC will select participants from among those who express interest and how participants will be notified about their participation status.

Prior to analyzing the input gathered through these conversations, will remove all personally identifiable information, which is any information that can be used to distinguish or trace an individual's identity, such as name, date and place of birth.

Themes

During the conversations, CDC will invite input specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments (*e.g.,* exercise therapy or cognitive behavioral therapy). These topics are:

- Experiences managing pain, which might include benefits, risks, and/or harms of the pain management options listed above.
- Experiences choosing among the pain management options listed above, including considering factors such as each option's accessibility, cost, benefits, and/or risks.
- Experiences getting information needed to make pain management decisions.

Participant Selection Procedure

From people who express interest by the deadline, CDC will identify persons at random from within the targeted populations (*i.e.* patients with acute or chronic pain, patients' family members and/or caregivers, and healthcare providers who care for patients with pain or conditions that can complicate pain management (*e.g.,* opioid use disorder or overdose)). CDC will seek to balance representation on factors including pain type (acute or chronic); experience (mostly benefitted, mostly harmed, neither, both); and role (provider, patient, family member and/or caregiver). Identified participants will receive an invitation to participate, as well as possible scheduling reminders, by email or phone calls.

Further Communications

Persons who wish to receive information related to CDC's ongoing work specific to drug overdose prevention (including the ongoing response to the opioid overdose epidemic) as well as other updates (*e.g.,* pertaining to resources and tools) may sign up at: *www.cdc.gov/emailupdates* and select topics of interest. Available offerings include:

- Subscription Topics: Injury, Violence & Safety
- Subtopic: Drug Overdose News

Resources

CDC's National Center for Injury Prevention and Control is committed to suicide prevention. If you are in immediate danger, please call 9–1–1 or go to your nearest emergency department. If you or someone you care for needs help, you may contact the National Suicide Prevention Lifeline (*https://suicidepreventionlifeline.org*) or your local crisis line. The National Disaster Distress Helpline is available to anyone experiencing emotional distress related to COVID–19. Call 1–800–985–5990 or text TalkWithUs to 66746 to speak to a caring counselor. For additional help, please see the many helpful resources at *https://suicidepreventionlifeline.org/current-events/supporting-your-emotional-well-being-during-the-covid-19-outbreak/*

Applicability of the Paperwork Reduction Act

The data are being collected under OMB Control Number 0920–1050, Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery, Expiration date: May 31, 2022.

Dated: July 17, 2020.

Sandra Cashman,

Executive Secretary, Centers for Disease Control and Prevention.

[FR Doc. 2020–15855 Filed 7–21–20; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2020–N–1450]

Electronic Submissions; Data Standards; Support for the International Institute of Electrical and Electronics Engineers Bioinformatics Computations and Analyses Standard for Bioinformatic Workflows

AGENCY: Food and Drug Administration, Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing support for use in regulatory submissions the current version of the International Institute of Electrical and Electronics Engineers (IEEE) bioinformatics computations and analyses standard for bioinformatic workflows (BioCompute) and an update to include this standard in the FDA Data Standards Catalog for the submission of high-throughput sequencing (HTS) data in new drug applications (NDAs), abbreviated new drug applications (ANDAs), biologics license applications (BLAs), and investigational new drug applications (INDs) to the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Food Safety and Applied Nutrition (CFSAN).

DATES: Submit either electronic or written comments on the notice by August 21, 2020.

ADDRESSES: You may submit either electronic or written comments at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–